4 Benito AI, Bryant E, Loken MR, Sale GE, Nash RA, John Gass M et al. T-cell acute lymphoblastic leukemia (T-ALL) arises from the malignant transformation of T-cell progenitors at various stages of development. 1 Although significant strides have been made in the treatment of pediatric T-ALL with more than 80% of the patients now being cured of their disease, 2 the early immature subtype of T-ALL has a dire prognosis with a 10-year overall survival of only 19%. 3, 4 Early immature T-ALL is characterized by a gene expression signature related to early T-cell precursors and a distinct immunophenotype: CD1a À , CD8 À , CD5 weak with expression of stem-cell/myeloid markers. 3, 4 In addition, this subtype of T-ALL harbors a distinct panel of mutations in genes that are commonly disrupted in acute myeloid leukemia. [4] [5] [6] Although the genetic lesions characterizing early immature T-ALL have recently been described, 6 the molecular basis underlying the inherent chemoresistance of this subtype of T-ALL remains largely unknown.
The high relapse rates of several lymphoid malignancies have been attributed to upregulation of anti-apoptotic BCL2 family members.
7 BH3 mimetics, a class of small molecules that mimic BH3-only pro-apoptotic proteins, engage pro-survival BCL2 family proteins to promote cell death.
8 Navitoclax (ABT-263) targets BCL-X L , BCL2 and BCLw; however, its use in the clinic has been limited because BCL-X L inhibition results in thrombocytopenia. [9] [10] [11] [12] ABT-199, an investigational drug in clinical trials, is a potent BCL2 inhibitor that has minimal activity against BCL-X L and thus does not affect platelet survival. 12 ABT-199 elicits striking pro-apoptotic effects as a single agent on non-Hodgkin's lymphoma cell lines and chronic lymphocytic leukemia primary Accepted article preview online 17 December 2013; advance online publication, 10 January 2014
Letters to the Editor samples, both in vitro and in vivo. 12 We therefore explored the hypothesis that anti-apoptotic BCL2 family proteins are required for the aberrant survival and chemotherapy resistance of T-ALL cells.
To examine the role of anti-apoptotic BCL2 family members in T-ALL, we began by analyzing the expression levels of BCL2, BCL W , BCL-X L , MCL-1 and BFL-1 in early immature T-ALL compared with more-differentiated T-ALL cases, based on the gene expression array study of Coustan-Smith et al. 3 Expression levels of both BCL2 and BCL W transcripts were significantly upregulated in early immature T-ALL compared with more-differentiated T-ALL (Figure 1a ), but the expression levels of BCL-X L , MCL-1 and BFL-1 Values in (a, c-f ) are means ± SD, and represent three biological replicates. Statistical significance was determined by two-tailed t-test, *Po0.05; **Po0.001; ***Po0.0005.
transcripts were not significantly different (Supplementary Figures  1a-c) . The LOUCY T-ALL cell line has been shown to have a transcriptional signature similar to early immature primary T-ALL cells, as compared with several more-differentiated T-ALL cell lines-CTV1, CUTLL1, DND41, HPB-ALL, KOP-TK1 and TAL1. 4 Therefore, we analyzed the expression levels of the antiapoptotic proteins BCL2, BCLw and BCL-X L by western blotting in a panel of eight T-ALL cell lines-LOUCY, ALL-SIL, CCRF-CEM, HSB2, SUPT-11, SKW-3/KE-37, MOLT4 and JURKAT (Figure 1b ). This analysis showed that LOUCY cells express relatively high levels of BCL2 and BCLw, and relatively low levels of BCL-X L , when compared with the seven T-ALL cell lines that are more differentiated. We then tested the relative sensitivity of LOUCY cells and the other seven more-differentiated T-ALL cell lines to the BH3 mimetic ABT-263, which binds avidly to BCL2, BCL W and BCL-X L , and ABT-199, which is specific for BCL2. Interestingly, LOUCY cells were exquisitely sensitive to both ABT-263 (Figure 1c ; IC50 ¼ 43 nM) and (Figure 1d ; IC50 ¼ 18 nM), indicating that these cells depend on BCL2 for survival, even though they also expressed relatively high levels of BCL W . The IC50 of ABT-199 was substantially higher in the more-differentiated T-ALL cell lines compared with that of ABT-263 (Po0.02; SUPT-11 cells were excluded from the comparison as they are insensitive to ABT-263 treatment), suggesting that BCL-X L has an important antiapoptotic role in these more-differentiated T-ALL cells.
Next, we used Annexin V and propidium iodide (PI) staining to document that the inhibitors acted by inducing apoptosis. (Figure 1e) . Together, these data show that the early immature LOUCY cells are highly sensitive to BCL2 inhibition and indicate that they depend on BCL2 for survival.
To determine which T-ALL cells are resistant to chemotherapy, we treated the eight T-ALL cell lines with etoposide, dexamethasone, rapamycin, vincristine and doxorubicin ( Supplementary  Figures 3a-e) , as well as cytarabine (Figure 2a ). In agreement with the poor prognosis of patients with early immature T-ALL, LOUCY cells showed a relatively poor response to each of these chemotherapeutic agents, with an IC50 greater than 5000 nM for cytarabine ( Figure 2a) .
Next, we sought to determine whether a combination of ABT-199 with cytarabine could synergistically induce cell death in early immature and more-differentiated T-ALL cell lines. To this end, we treated LOUCY and JURKAT cells with serial dilutions of ABT-199 and cytarabine in combination and analyzed relative cell viability. In LOUCY cells, ABT-199 and cytarabine showed very strong synergism (Figure 2b) , with an average combination index (CI) of 0.06 (where a CI of 1 indicates an additive effect, CIo1 is synergistic and CI41 antagonistic). This combination showed modest synergism in JURKAT cells with an average CI of 0.72 (Figure 2c) .
To understand the cellular basis for the synergy of ABT-199 and cytarabine in early immature LOUCY cells, we performed cell cycle and apoptosis analyses. Cytarabine resulted in S-phase arrest after 24 h of incubation (Figure 2d and Supplementary Figure 4c) . In LOUCY cells, the combination treatment led to a nearly two-fold increase in sub-G1 population compared with that found with single-agent treatments (Figure 2d and Supplementary Figures  4a-d) . Importantly, the combination treatment also led to a significant increase in apoptosis measured by Annexin V and PI, as compared with the result with either drug alone (Figure 2e and Supplementary Figures 5a-c) .
In conclusion, our study shows that ABT-199 in submicromolar doses is not active in the killing of most cell lines representing more-differentiated human T-ALL cells. Intriguingly, the LOUCY cell line, the only T-ALL cell line with the gene expression signature of early immature T-ALL, showed exquisite sensitivity to ABT-199. In addition, ABT-199 showed striking synergy with cytarabine in the LOUCY cell line. Although our results are based on a single early immature T-ALL cell line, they are potentially important because primary cases of early immature T-ALL are highly resistant to current regimens of combination chemotherapy. As other early immature T-ALL cell lines are not available, the possibility that ABT-199 may show clinically significant activity in early immature T-ALL cases will need to be pursued in 'primagraft models' of this disease (established by engrafting early immature T-ALL samples directly into immunodeprived mice). Alternatively, as ABT-199 is now in clinical trials for chronic lymphocytic leukemia and as primagraft models of early immature T-ALL cells have not been reported, this BH3 mimetic could be tested directly in phase I/II clinical trials, either alone or in combination with cytarabine, for relapsed/refractory early immature T-ALL patients.
